UBS analyst Matthew Taylor downgraded Insulet to Neutral but raised his price target to $160 from $155, saying that while there is no expected negative catalyst for the stock, he sees its price performance cooling off following a strong run. The analyst remains positive on the "form factor" of the company's product as well as its rich pipeline and strong management team. However, although he still sees the potential for Insulet to sustain revenue growth of over 20% next year, he believes that the positive are reflected in its valuation following a 94% year-to-date run-up.